Abstract
Tarlatamab (tarlatamab-dlle) is the first bispecific T-cell engager (BiTE) therapy approved for treating a solid tumor, specifically small cell lung cancer, making it the first of its kind. It targets delta-like ligand 3 antigens on the surface of tumor cells while activating the patient's T cells. This article discusses BiTE therapy as well as its boxed warnings and precautions that nurses need to know to provide optimum patient care.